New infant vaccine tested to fight pneumonia
NCT ID NCT05412030
Summary
This study tested a new vaccine called AFX3772, designed to protect healthy infants from serious pneumococcal infections like pneumonia. Researchers compared three different versions of the new vaccine to two existing, approved vaccines (Prevnar 13 and Prevnar 20) to see which was safest and triggered the best immune response. The trial involved 388 infants around 2 months old and focused on side effects and how well the body produced protective antibodies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA, BACTERIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Jonesboro, Arkansas, 72401, United States
-
GSK Investigational Site
Los Angeles, California, 90057, United States
-
GSK Investigational Site
Miami, Florida, 33184, United States
-
GSK Investigational Site
Pensacola, Florida, 32503, United States
-
GSK Investigational Site
Saint Augustine, Florida, 32086, United States
-
GSK Investigational Site
Tampa, Florida, 33613, United States
-
GSK Investigational Site
Nampa, Idaho, 83702, United States
-
GSK Investigational Site
Bardstown, Kentucky, 40004, United States
-
GSK Investigational Site
Lexington, Kentucky, 40517, United States
-
GSK Investigational Site
Louisville, Kentucky, 40291, United States
-
GSK Investigational Site
Covington, Louisiana, 70433, United States
-
GSK Investigational Site
Haughton, Louisiana, 71037, United States
-
GSK Investigational Site
Lafayette, Louisiana, 70508, United States
-
GSK Investigational Site
New Orleans, Louisiana, 70119, United States
-
GSK Investigational Site
Mankato, Minnesota, 56001, United States
-
GSK Investigational Site
Missoula, Montana, 59804, United States
-
GSK Investigational Site
Hastings, Nebraska, 68901, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45245, United States
-
GSK Investigational Site
Tulsa, Oklahoma, 74104, United States
-
GSK Investigational Site
Cranberry Township, Pennsylvania, 16006, United States
-
GSK Investigational Site
Jefferson Hills, Pennsylvania, 15025, United States
-
GSK Investigational Site
N. Huntingdon, Pennsylvania, 15642, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15213, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15217, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15234, United States
-
GSK Investigational Site
Charleston, South Carolina, 29407, United States
-
GSK Investigational Site
Greenville, South Carolina, 29607, United States
-
GSK Investigational Site
Spartanburg, South Carolina, 29301, United States
-
GSK Investigational Site
Brownsville, Texas, 78520, United States
-
GSK Investigational Site
Dallas, Texas, 75230, United States
-
GSK Investigational Site
Dickinson, Texas, 77539, United States
-
GSK Investigational Site
Houston, Texas, 77065, United States
-
GSK Investigational Site
Houston, Texas, 77077, United States
-
GSK Investigational Site
Houston, Texas, 77087, United States
-
GSK Investigational Site
McAllen, Texas, 78504, United States
-
GSK Investigational Site
Richmond, Texas, 77469, United States
-
GSK Investigational Site
Layton, Utah, 84041, United States
-
GSK Investigational Site
Roy, Utah, 84067, United States
-
GSK Investigational Site
Salt Lake City, Utah, 84107, United States
-
GSK Investigational Site
South Jordan, Utah, 84095, United States
-
GSK Investigational Site
Syracuse, Utah, 84075, United States
-
GSK Investigational Site
Norfolk, Virginia, 68701, United States
-
GSK Investigational Site
Bayamón, 960, Puerto Rico
-
GSK Investigational Site
Caguas, 00725, Puerto Rico
-
GSK Investigational Site
Ponce, 00716, Puerto Rico
-
GSK Investigational Site
San Juan, 00935-6528, Puerto Rico
Conditions
Explore the condition pages connected to this study.